Eugia Pharma Specialities restarts production at terminally sterilized product lines
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The product is expected to be launched in December 2023
The plant is yet to start commercial operations
The product is expected to be launched in FY25
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Subscribe To Our Newsletter & Stay Updated